Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed.

Business Wire • Jan 12, 2026

RBOT Enters Strategic Software Partnership to Streamline Development

Vicarious Surgical inks a software execution partnership to streamline development, cut costs and improve predictability.

Zacks Investment Research • Dec 30, 2025

Vicarious Surgical Announces Strategic Software Execution Partnership to Streamline Operations

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has entered into a strategic partnership agreement with a global digital engineering and software development services firm. This engagement is a central component of the Company's broader operating model transformation, designed to improve execution, increase development predictabil.

Business Wire • Dec 29, 2025

NYSE to Commence Delisting Proceedings with Respect to Warrants of Vicarious Surgical Inc. (RBOT WS)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants (“Warrants”) — ticker symbol RBOT WS — thirty (30) whole warrants are exercisable to purchase one share of Class A common stock of Vicarious Surgical Inc. (the “Company”) from the NYSE. Trading in these Warrants on the NYSE will be suspended immediately. Trading in the Company's Class A common stock — tick.

Business Wire • Dec 16, 2025

Vicarious Surgical Announces Full Year 2026 Cash Burn Guidance

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT, RBOT.WS) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced its full-year 2026 cash burn guidance. Vicarious Surgical expects full-year 2026 cash burn of approximately $35 million, representing a $10 million improvement from the Company's recently updated 2025 guidance of $45 million. Cash needs beyond existing cash resources to achieve desi.

Business Wire • Dec 15, 2025

Vicarious Surgical Announces Reduction in 2025 Cash Burn Outlook

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT, RBOT.WS) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced an update to full-year 2025 financial guidance. Vicarious Surgical now expects full-year 2025 cash burn of approximately $45 million, representing a $5 million improvement from its previous guidance of $50 million. The improved guidance reflects disciplined cost management initiativ.

Business Wire • Dec 3, 2025

Vicarious Surgical to Participate in the Piper Sandler 37th Annual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that the Company will participate in the upcoming Piper Sandler 37th Annual Healthcare Conference. Vicarious Surgical's management is scheduled to participate in a fireside discussion on Wednesday, December 3, 2025, at 4:30 p.m. Eastern Standard Time. Interes.

Business Wire • Nov 19, 2025

Vicarious Surgical Inc. (RBOT) Q3 2025 Earnings Call Transcript

Vicarious Surgical Inc. ( RBOT ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Stephen From - CEO & Director Sarah Romano - CFO & Treasurer Conference Call Participants Marissa Bych - Gilmartin Group LLC Joshua Jennings - TD Cowen, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good afternoon. Thank you for attending the Vicarious Surgical's 2025 Third Quarter Earnings Call.

Seeking Alpha • Nov 12, 2025

Vicarious Surgical Reports Third Quarter 2025 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the third quarter ended September 30, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, November 12, 2025. “Since stepping into this role three months ago, my focus has been on sharpening our execution and.

Business Wire • Nov 12, 2025

Vicarious Surgical to Report Third Quarter 2025 Financial Results on November 12, 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will now report financial results for the third quarter ended September 30, 2025 after the market closes on Wednesday, November 12, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested.

Business Wire • Nov 6, 2025